Document:

Exhibit 10.1

 

ONCONOVA THERAPEUTICS, INC.

 

AMENDMENT TO EMPLOYMENT AGREEMENT

 

THIS AMENDMENT TO
EMPLOYMENT AGREEMENT (this “Amendment”), is made as of June 10, 2022 (the “Amendment Effective
Date”), by and between Onconova Therapeutics, Inc., a Delaware corporation (the
 “Company”), and Mark Guerin (the “Employee”). Capitalized terms used and not
otherwise defined herein shall have the meanings ascribed to such terms in the Agreement (as defined below).

 

RECITALS

 

	A.	The Company and Employee previously entered into an Employment Agreement dated July 1, 2015 (the
 “Agreement”).

 

	B.	Employee was previously promoted to Chief Financial Officer effective September 1, 2016.

 

	C.	Employee has been promoted to Chief Operating Officer effective as of June 10, 2022 and the parties
hereto wish to amend the Agreement to revise certain provisions in connection with Employee’s promotion as set forth herein.

 

AMENDMENT

 

The parties hereto hereby amend the Agreement
as follows, effective as of the Amendment Effective Date.

 

	1.	Section 2 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“Duties. Subject
to all the terms and conditions hereof, the Company shall employ Employee, and Employee shall serve the Company as Chief Operating Officer
and Chief Financial Officer. Employee shall report directly to the Chief Executive Officer of the Company. As Employee’s position
is a full-time position, Employee agrees to devote his full-time effort, attention, and energies, from our Newtown, Pennsylvania office
or from offsite, to this position and to the promotion of the business and interests of the Company. Employee will not render any professional
services or engage in any activity which might be competitive with, adverse to the best interest of, or create the appearance of a conflict
of interest with the Company. Employee agrees to abide by the policies, rules and regulations of the Company as they may be amended
from time to time. Employee may not engage in outside employment or consulting without first obtaining prior express permission of the
Company.”

 

	2.	Section 3(a) is hereby deleted in its entirety and replaced with the following:

 

“Salary. 
For all services rendered by Employee under this Agreement, the Company agrees to pay Employee at an initial annualized rate of four hundred
seventy five thousand ($475,000) (the “Base Salary”), in bi-weekly installments in accordance with the Company’s normal
payroll cycle, less customary and legally required withholdings.”

 

     

     

    

 

	3.	Section 4(d). Section 4 of the Agreement is hereby amended by adding the following sentence
immediately following Section 4(d)(5):

 

“The payments and benefits
set forth in Section 4(d)(3), (4) and (5) shall only be paid if Employee signs and does not revoke a release and waiver
of claims in a form approved by the Company and such release becomes effective and irrevocable within 60 days of Employee’s cessation
of employment and Employee’s continued compliance with the restrictive covenants in Sections 5, 6 and 7 in this Agreement.”

 

	4.	Section 19. A new Section 19 is added to the Agreement, as follows:

 

“Whistleblower Protections
and Trade Secrets. Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits Employee from reporting
possible violations of federal law or regulation to any United States governmental agency or entity in accordance with the provisions
of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley
Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an
award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding
anything to the contrary in this Agreement: (i) Employee shall not be in breach of this Agreement, and shall not be held criminally
or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence
to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation
of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal; and (ii) if Employee files a lawsuit for retaliation by the Company for reporting a suspected
violation of law, Employee may disclose the trade secret to Employee’s attorney, and may use the trade secret information in the
court proceeding, if Employee files any document containing the trade secret under seal, and does not disclose the trade secret, except
pursuant to court order.”

 

	5.	This Amendment shall be and, as of the Amendment Effective Date, is hereby incorporated in and forms a
part of, the Agreement.

 

	6.	Except as expressly provided herein, all terms and conditions of the Agreement shall remain in full force
and effect.

 

(Signature page follows)

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment
as of the date first written above.

 

	 	ONCONOVA THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/ Steven Fruchtman
	 	 	Name: Steven Fruchtman, M.D.
	 	 	Title: President and Chief Executive Officer
	 	 	 
	 	 	EMPLOYEE
	 	 	 
	 	 	/s/ Mark Guerin
	 	 	Mark GuerinExhibit 10.1

 

SHAREHOLDER VOTING AND SUPPORT AGREEMENT

 

This Shareholder Voting And
Support Agreement (this “Agreement”), dated as of June 9, 2022, is made and entered into by and among Holisto
Ltd., an Israeli company (the “Company”), Moringa Acquisition Corp, a Cayman Islands exempted company (“SPAC”),
and the party listed on the signature pages hereto as a “Shareholder” (the “Shareholder”).

 

RECITALS

 

WHEREAS, concurrently
herewith, SPAC, Holisto MergerSub, Inc., a Cayman Islands exempted company and wholly-owned subsidiary of the Company (“Merger
Sub”), and the Company are entering into a Business Combination Agreement in substantially the form provided to the Shareholder
and is attached hereto as Exhibit A (as may be amended, supplemented, restated or otherwise modified from time to time by the Company
and SPAC, the “Business Combination Agreement”) to effect a transaction resulting in the initial registration
of the Company’s Ordinary Shares (or initial or continued registration of the class of securities exchanged for Company securities
in such transaction) under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder,
the “Exchange Act”) (or equivalent securities law of another jurisdiction) (the “SPAC Transaction”);

 

WHEREAS, immediately
prior and subject to the closing of the SPAC Transaction (the “Closing”), each Preferred A Share, Preferred
A-1 Share, Preferred A-2 Share (collectively, the “Preferred Shares”) and Ordinary A Share of the Company, NIS
0.01 par value each, that is outstanding immediately prior to the Closing, shall be converted automatically into one Ordinary Share of
the Company (the “Conversion”), and immediately following such conversion, the Company shall effect a share
split, to become effective as of immediately prior to the Closing, pursuant to which all issued and unissued Ordinary Shares of the Company
shall be converted into the number of Company Ordinary Shares computed by multiplying each such Company Ordinary Share by the a certain
conversion ratio (the “Capital Restructuring”) all as detailed in the Business Combination Agreement;

 

WHEREAS, at the Effective
Time, upon the terms and subject to the conditions of the Business Combination Agreement and in accordance with the Cayman Islands Companies
Law (2020 Revision), as amended or restated from time to time, Merger Sub will merge with and into SPAC (the “Merger”),
with SPAC continuing as the surviving company after the Merger, as a result of which SPAC will become a direct, wholly-owned subsidiary
of the Company;

 

WHEREAS, as of the
date hereof, the Shareholder is the record and “beneficial owner” (within the meaning of Rule 13d-3 under the Exchange Act
of and is entitled to dispose of and vote (including, without limitation, by proxy or power of attorney) Company Shares and such number
of Company Warrants (if any) set forth on the signature pages hereto (collectively, the “Owned Shares”; the
Owned Shares and any additional Company Ordinary Shares and/or Company Ordinary A Shares and/or Company Preferred Shares (or any securities
convertible into or exercisable or exchangeable for Company Ordinary Shares and/or Company Ordinary A Shares and/or Company Preferred
Shares) in which the Shareholder has or acquires record or beneficial ownership after the date hereof, including by purchase, as a result
of a share dividend, share split, recapitalization, combination, reclassification, exchange or change of such shares, or upon exercise
or conversion of any securities, the “Covered Shares”); and

 

WHEREAS, in anticipation
of, and as a condition and inducement to the willingness of SPAC to enter into the Business Combination Agreement, SPAC, the Company and
the Shareholder are entering into this Agreement.

 

     

     

    

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, SPAC,
the Company and the Shareholder hereby agree as follows:

 

1. Agreement
to Vote. The Shareholder irrevocably and unconditionally agrees that, at any meeting of the shareholders of the Company (whether annual
or special and whether or not an adjourned or postponed meeting) including any class meetings, class votes or class consents, and in connection
with any written consent of shareholders of the Company, the Shareholder shall, and shall cause any other holder of record of any of the
Shareholder’s Covered Shares to: (a) if and when such meeting is held, appear at such meeting (in person or by proxy), and
if a quorum is not present, to vote (in person or by proxy) in favor of adjournment of such meeting of the shareholders to a later date,
as in accordance with the Company’s Articles of Association as in effect at such time; (b) vote, in person or by proxy, or
validly execute and deliver any written consent with respect to all of the Shareholder’s Covered Shares in favor of the resolutions
in the form attached hereto as Exhibit B, and any other resolutions in favor of (i) the Merger and the adoption of the Business
Combination Agreement (ii) the Conversion (iii) the Capital Restructuring, and (iv) any other matters necessary or reasonably requested
by the Company for consummation of the Merger and the other transactions contemplated by the Business Combination Agreement; (c)
vote, in person or by proxy, or validly execute and deliver any written consent with respect to all of the Shareholder’s Covered
Shares against (A) any transaction, action or agreement of any kind (other than the SPAC Transaction) concerning the sale or transfer
of (x) all or any material part of the business or assets of the Company or (y) any of the shares or other equity interests or profits
of the Company, that would reasonably be expected to (i) frustrate the purposes of, impede, interfere with, delay, postpone or adversely
affect the SPAC Transaction (including the consummation thereof), (ii) result in a breach of any covenant, representation or warranty
or other obligation or agreement of the Company under the Business Combination Agreement, or cause any of the conditions to Closing set
forth in the Business Combination Agreement not to be fulfilled or satisfied, or (iii) result in a breach of any covenant, representation
or warranty or other obligation or agreement of the Shareholder contained in this Agreement and (B) any merger agreement or merger (other
than the Business Combination Agreement and the Merger), consolidation, combination, sale of all or substantially all assets, scheme of
arrangement, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company.

 

2. Proxy.

 

(a) The
Shareholder hereby irrevocably and unconditionally, to the fullest extent permitted by applicable Law, appoints the Chief Executive Officer
of the Company, or any designee of the Company as approved by the board of directors of the Company, as the Shareholder’s attorney-in-fact
and proxy with full power of substitution, to vote, express consent or dissent and otherwise act (by written consent or otherwise) with
respect to the Covered Shares, solely on the matters and in the manner specified in Section ‎
‎1. THE PROXIES AND POWERS OF ATTORNEY GRANTED PURSUANT TO THIS SECTION ‎2
ARE IRREVOCABLE AND COUPLED WITH AN INTEREST. The Shareholder hereby affirms that the irrevocable proxy granted by Shareholder pursuant
to this Section 2 is granted in consideration of SPAC considering entering into this Agreement and the Business Combination Agreement
and that such irrevocable proxy is given to secure the performance of the duties of the Shareholder under this Agreement. The proxies
and powers of attorney shall not be terminated by any act of the Shareholder or by operation of law, by lack of appropriate power or authority,
or by the occurrence of any other event or events and shall be binding upon all successors, assigns, heirs, beneficiaries and legal representatives
of the Shareholder. The Shareholder hereby revokes all other proxies and powers of attorney on the matters specified in this Section
‎2 with respect to the Covered Shares that the Shareholder may
have previously appointed or granted, and no subsequent proxy or power of attorney shall be given or written consent executed (and if
given or executed, shall not be effective) by the Shareholder with respect to any Covered Shares. All authority herein conferred or agreed
to be conferred shall survive the death, bankruptcy or incapacity of the Shareholder and any obligation of the Shareholder under this
Agreement shall be binding upon the heirs, personal representatives, and successors of the Shareholder.

 

    2

     

    

 

3. Termination.
This Agreement shall terminate, and no party shall have any further obligations or liabilities under this Agreement, upon the earliest
of (i) termination of the Business Combination Agreement in accordance with its terms or (ii) the time this Agreement is terminated upon
the mutual written agreement of SPAC, the Company and the Shareholder (the earliest such date under clause (i) and (ii) being referred
to herein as the “Termination Date”); provided, that the provisions set forth in Sections ‎8
to ‎16 below shall survive the termination of this Agreement;
provided further, that termination of this Agreement shall not relieve any party hereto from any liability for any willful breach
of, or actual fraud in connection with, this Agreement prior to such termination.

 

4. Representations
and Warranties of the Shareholder. The Shareholder hereby represents and warrants to the Company and SPAC as to itself, as of the
date hereof and as of the Closing, that the Shareholder has full legal capacity, power and authority to execute and deliver this Agreement
and to perform its obligations hereunder. This Agreement constitutes valid and binding obligation of the Shareholder, enforceable in accordance
with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement
of creditors’ rights generally and general principles of equity.

 

5. The
Shareholder hereby agrees not to, directly or indirectly, prior to the Termination Date, except in connection with the consummation of
the Merger, (i) sell, transfer, encumber, assign or otherwise dispose of, either voluntarily or involuntarily (collectively, “Transfer”),
or enter into any Contract, option or other arrangement (including profit sharing arrangement) with respect to the Transfer of any of
the Shareholder’s Covered Shares; (ii) grant any proxies or enter into any voting arrangement, whether by proxy, voting agreement,
voting trust, voting deed or otherwise (including pursuant to any loan of any Covered Shares), or enter into any other agreement, with
respect to any Covered Shares (in each case, other than the Proxy granted to the Company in accordance with this Agreement); (iii) publicly
announce any intention to effect any transaction specified in clauses (i) or (ii); or (iv) take any action that would make any representation
or warranty of the Shareholder contained herein untrue or incorrect or have the effect of preventing, disabling or delaying the Shareholder
from performing its obligations under this Agreement.

 

6. Further
Assurances, Instruments and Efforts. From time to time, at SPAC’s or Company’s request and without further consideration,
the Shareholder shall execute and deliver such additional documents, including without limitation a lock-up agreement in substantially
the form that the Chief Executive Officer of the Company shall be requested to sign in connection with the SPAC Transaction, and take
all such further action as may be reasonably necessary to effect the actions and consummate the transactions contemplated by this Agreement
and by the Business Combination Agreement, and Shareholder shall use its commercially reasonable efforts, and shall reasonably cooperate
with the Company and SPAC, to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary,
proper or advisable to consummate the SPAC Transaction (including the delivery of any information required for all applicable notices
and filings and for the receipt of all applicable consents of governmental authorities and third parties) and to comply as promptly as
practicable with all requirements of governmental authorities applicable to the SPAC Transaction, including any regulatory application
or filing required or advisable in connection with the SPAC Transaction (including filings with the SEC or Nasdaq). The Shareholder further
agrees not to commence or participate in, and to take all actions necessary to opt out of any class action with respect to, any action
or claim, derivative or otherwise, against SPAC, the Company or any of their respective Affiliates, successors and assigns relating to
the negotiation, execution or delivery of this Agreement, the Business Combination Agreement or the consummation of the transactions contemplated
hereby and thereby (including the Capital Restructuring).

 

    3

     

    

 

7. Waiver
of Rights. By executing this Agreement, the Shareholder, as and to the extent applicable thereto, hereby irrevocably, absolutely and
unconditionally waives any and all preemptive rights, anti-dilution rights, first refusal rights, over allotment rights, co-sale rights,
veto rights and any other participation rights and all similar rights or other limitations that the Shareholder has or may have (whether
derived from the Company’s Articles of Association as in effect on the date hereof, any agreement, other arrangement or any applicable
law, including without limitation, Section 290 of the Israeli Companies Law 1999 or otherwise), in connection with any and all investments
made in the Company and/or any subsidiary thereof, whether by way of an equity investment, or by way of convertible debt, or in any other
manner whatsoever, in furtherance of, or in connection with, or pursuant to the SPAC Transaction and/or the Merger and/or the Business
Combination Agreement.

 

8. Disclosure.
The Shareholder hereby authorizes the Company and SPAC to publish and disclose in any announcement or disclosure required by the SEC (or
as otherwise required by any applicable securities laws or any other securities authorities), or include in any document or information
required to be filed with or furnished to the SEC or Nasdaq, the Shareholder’s identity and ownership of the Covered Shares and
the nature of the Shareholder’s obligations under this Agreement and, if deemed appropriate by the Company or SPAC, a copy of this
Agreement.

 

9. Confidentiality.
The Shareholder (including its affiliates, directors, partners, officers, investors, employees and agents) agrees to retain in strict
confidence the existence and terms of this Agreement, the negotiations between the Company and SPAC, any information related to the Business
Combination Agreement and the SPAC Transaction and all nonpublic information related to SAPC and the SPAC identity, and further agree
that it will not disclose to any third party, or permit the use or disclosure to any third party of such information or any information
obtained from or revealed hereunder.

 

10. Amendment
and Modification. This Agreement may not be amended, modified or supplemented in any manner, whether by course of conduct or otherwise,
except by an instrument in writing signed by SPAC, the Company and the Shareholder. Any party to this Agreement may, at any time prior
to the Termination Date, waive any of the terms or conditions of this Agreement, or agree to an amendment or modification to this Agreement
in the manner contemplated by this Section ‎10 or Section
‎11, as applicable.

 

11. Waiver.
No failure or delay by any party hereto exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
The rights and remedies of the parties hereto hereunder are cumulative and are not exclusive of any rights or remedies which they would
otherwise have hereunder. Any agreement on the part of a party hereto to any such waiver shall be valid only if set forth in a written
instrument executed and delivered by such party.

 

12. Notices.
Any notice required or permitted by this instrument will be deemed sufficient when delivered personally or by overnight courier or sent
by email to the relevant address listed on the signature page or If to the Shareholder, to such address indicated on the Company’s
records with respect to the Shareholder or to such other address or addresses as the Shareholder may from time to time designate in writing,
or 48 hours after being deposited in the mail as certified or registered mail with postage prepaid, addressed to the party to be notified
at such party’s address listed on the signature page, as subsequently modified by written notice.

 

13. Governing
Law and Jurisdiction. All rights and obligations hereunder will be governed by the laws of the State of Israel, without regard to
its conflicts of law provisions. Any dispute arising under or in relation to this Agreement shall be resolved exclusively in the competent
court for Tel Aviv-Jaffa district, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of such court.

 

    4

     

    

 

14. Assignment;
Successors. No party hereto shall assign this Agreement or any part hereof without the prior written consent of the other parties.
Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns. Any attempted assignment in violation of the terms of this Section ‎‎13
shall be null and void, ab initio.

 

15. Enforcement.
The parties hereto agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would
occur in the event that the parties do not perform their obligations under the provisions of this Agreement in accordance with its specified
terms or otherwise breach such provisions. The parties hereto acknowledge and agree that (a) the parties shall be entitled to an injunction,
specific performance, or other equitable relief, to prevent breaches of this Agreement and to enforce specifically the terms and provisions
hereof, including the Shareholder’s obligations to vote its Covered Shares as provided in this Agreement, without proof of damages,
prior to the valid termination of this Agreement, this being in addition to any other remedy to which they are entitled under this Agreement,
and (b) the right of specific enforcement is an integral part of the transactions contemplated by this Agreement and without that right,
none of the parties would have entered into this Agreement. Each party agrees that it will not oppose the granting of specific performance
and other equitable relief on the basis that the other parties have an adequate remedy at applicable Law or that an award of specific
performance is not an appropriate remedy for any reason at applicable Law or equity. The parties acknowledge and agree that any party
seeking an injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in
accordance with this Section ‎15 shall not be required to provide
any bond or other security in connection with any such injunction.

 

16. Counterparts.
This Agreement and any amendment hereto may be executed in one or more counterparts, each of which shall be deemed to be an original,
but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement
or any amendment hereto by electronic means, including docusign, e-mail, or scanned pages shall be effective as delivery of a manually
executed counterpart to this Agreement or any amendment hereto.

 

17. Trust
Account Waiver. The Shareholder agrees, acknowledges and represents that it understands that SPAC has established its trust account
(the “Trust Account”) for the benefit of the public stockholders and that SPAC may disburse monies from the
Trust Account only: (A) to the public stockholders in the event of the conversion of their shares upon consummation of a business combination
or amendment to SPAC’s certificate of incorporation relating to pre-business combination activity, (B) to the public stockholders
in connection with SPAC’s liquidation in the event SPAC is unable to consummate a business combination within the required time
period or (C) to SPAC concurrently with, or after it consummates a business combination, and (ii) agrees that it does not have any right,
title, interest or claim of any kind in or to any monies of the Trust Account (“Claim”) and waives any Claim
it may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with SPAC and will not seek recourse
against the Trust Account for any reason whatsoever.

 

[The remainder of this page is intentionally
left blank]

 

    5

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed (where applicable, by their respective officers or other authorized Persons thereunto
duly authorized) as of the date first written above.

 

	 	MORINGA ACQUISITION CORP
	 	 	 
	 	By:	
	 	 	Name:
	 	 	Title:
	 	 	 
	 	HOLISTO LTD.
	 	 	 
	 	By:	
	 	 	Name:
	 	 	Title:

 

[Signature Page to Shareholder Voting and Support
Agreement]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Agreement to be executed (where applicable, by their respective officers or other authorized Persons thereunto
duly authorized) as of the date first written above.

 

	 	SHAREHOLDER
	 	 	 
	 	By:	
	 	 	Name:
	 	 	Title:

 

The Shareholder is the record and “beneficial
owner” (within the meaning of Rule 13d-3 under the Exchange Act) of and is entitled to dispose of and vote the following securities
of the Company which represent the only shares, warrants, notes, evidence of indebtedness, convertible loan (and interest thereon) or
instrument, or other rights or securities directly or indirectly convertible, exchangeable or exercisable into share capital of the Company,
and any rights to acquire or receive any of the foregoing (including by virtue of any convertible loan previously converted (if any),
any anti-dilution rights, rights of first refusal or first offer, preemptive rights or any other similar rights), to which the Shareholder
is or may be entitled:

 

	Number of Company Ordinary Shares	 
	Number of Company Ordinary A Shares	 
	Number of Company Preferred Share	 
	Number of Company Ordinary Shares issuable upon exercise of warrant	 
	Number of Company Ordinary A Shares issuable upon exercise of warrant	 
	Number of Company Preferred Shares issuable upon exercise of warrant	 

   

[Signature Page to Shareholder Voting and Support
Agreement]

 

    7

     

    

 

EXHIBIT A

 

Form of BCA

 

 

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]